Current Prostate Reports

, Volume 5, Issue 1, pp 21–26

Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression



Benign prostatic hyperplasia (BPH) is the most common urologic affliction in aging men, leading to adverse clinical outcomes in a significant proportion of the population. Serum prostate-specific antigen (PSA) has been established as a marker for prostate cancer for the past two decades but more recently has been recognized as an equally important marker of BPH presence and progression. Over this time, the discovery and study of multiple isoforms of PSA has led to even more sensitive and specific methods to differentiate BPH from prostate cancer. Herein we review the expression, processing, and biochemistry of PSA and its derivatives and discuss the potential of these isoforms, both individually and in combination, to serve as determinants of BPH severity and progression.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Emberton M, Andriole GL, de la Rosette J, et al.: Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003, 61:267–273.PubMedCrossRefGoogle Scholar
  2. 2.
    Jacobsen SJ, Girman CJ, Guess HA, et al.: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996, 155:595–600.PubMedCrossRefGoogle Scholar
  3. 3.
    Arrighi HM, Metter EJ, Guess HA, Fozzard JL: Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991, 38:4–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Roehrborn CG, McConnell J, Bonilla J, et al.: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000, 163:13–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Roehrborn CG, Boyle P, Gould AL, Waldstreicher J: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53:581–589.PubMedCrossRefGoogle Scholar
  6. 6.
    Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al.: Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003, 44:695–700.PubMedCrossRefGoogle Scholar
  7. 7.
    Chung BH, Hong SJ, Cho JS, Seong DH: Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 2006, 97:742–746.PubMedCrossRefGoogle Scholar
  8. 8.
    Roehrborn CG, Malice M, Cook TJ, Girman CJ: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210–216.PubMedCrossRefGoogle Scholar
  9. 9.
    Roehrborn CG, McConnell JD, Lieber M, et al.: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999, 53:473–480.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 1979, 17:159–163.PubMedGoogle Scholar
  11. 11.
    Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156–1161.PubMedCrossRefGoogle Scholar
  12. 12.
    Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909–916.PubMedCrossRefGoogle Scholar
  13. 13.
    Diamandis EP: Prostate specific antigen—new applications in breast and other cancers. Anticancer Res 1996, 16:3983–3984.PubMedGoogle Scholar
  14. 14.
    Robert M, Gibbs BF, Jacobson E, Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 1997, 36:3811–3819.PubMedCrossRefGoogle Scholar
  15. 15.
    Borgono CA, Michael IP, Diamandis EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257–280.PubMedGoogle Scholar
  16. 16.
    Lundwall A, Lilja H: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987, 214:317–322.PubMedCrossRefGoogle Scholar
  17. 17.
    Kumar A, Mikolajczyk SD, Goel AS, et al.: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997, 57:3111–3114.PubMedGoogle Scholar
  18. 18.
    Lilja H: Biology of prostate-specific antigen. Urology 2003, 62:27–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Villoutreix BO, Getzoff ED, Griffin JH: A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994, 3:2033–2044.PubMedCrossRefGoogle Scholar
  20. 20.
    Christensson A Lilja H: Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994, 220:45–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Stenman UH, Leinonen J, Alfthan H, et al.: A complex between prostate-specific antigen and alpha 1-antichy-motrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51:222–226.PubMedGoogle Scholar
  22. 22.
    Woodrum DL, Brawer MK, Partin AW, et al.: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998, 159:5–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Catalona WJ, Smith DS, Wolfert RL, et al.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274:1214–1220.PubMedCrossRefGoogle Scholar
  24. 24.
    Catalona WJ, Southwick PC, Slawin KM, et al.: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000, 56:255–260.PubMedCrossRefGoogle Scholar
  25. 25.
    Haese A, Graefen M, Noldus J, Hammerer P, et al.: Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 1997, 158:2188–2192.PubMedCrossRefGoogle Scholar
  26. 26.
    Mettlin C, Chesley AE, Murphy GP, et al.: Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 1999, 39:153–158.PubMedCrossRefGoogle Scholar
  27. 27.
    Stephan C, Lein M, Jung K, et al.: The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997, 79:104–109.PubMedCrossRefGoogle Scholar
  28. 28.
    Morote J, Encabo G, Lopez M, de Torres IM: Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 2000, 38:91–95.PubMedCrossRefGoogle Scholar
  29. 29.
    Canto EI, Singh H, Shariat SF, et al.: Serum BPSA out-performs both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004, 63:905–910.PubMedCrossRefGoogle Scholar
  30. 30.
    Mikolajczyk SD, Grauer LS, Millar LS, et al.: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50:710–714.PubMedCrossRefGoogle Scholar
  31. 31.
    Peter JC, Unverzagt TN, Krogh O, et al.: Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001, 61:957–962.PubMedGoogle Scholar
  32. 32.
    de Vries SH, Raaijmakers R, Blijenberg BG, et al.: Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer. Urology 2005, 65:926–930.PubMedCrossRefGoogle Scholar
  33. 33.
    Niemela P, Lovgren J, Karp M, et al.: Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 2002, 48:1257–1264.PubMedGoogle Scholar
  34. 34.
    Mikolajczyk SD, Marker KM, Millar LS, et al.: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958–6963.PubMedGoogle Scholar
  35. 35.
    Chan TY, Mikolajczyk SD, Lecksell K, et al.: Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003, 62:177–181.PubMedCrossRefGoogle Scholar
  36. 36.
    Catalona WJ, Bartsch G, Rittenhouse HG, et al.: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003, 170:2181–2185.PubMedCrossRefGoogle Scholar
  37. 37.
    Sokoll LJ, Chan DW, Mikolajczyk SD, et al.: Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology 2003, 61:274–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Khan MA, Sokoll LJ, Chan DW, et al.: Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15%. Urology 2004, 64:1160–1164.PubMedCrossRefGoogle Scholar
  39. 39.
    Naya Y, Fritsche HA, Bhadkamkar VA, et al.: Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 2004, 63:492–498.PubMedCrossRefGoogle Scholar
  40. 40.
    Bangma CH, Wildhagen MF, Yurdakul G, et al.: The value of (-7,-5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 2004, 93:720–724.PubMedCrossRefGoogle Scholar
  41. 41.
    Naya Y, Fritsche HA, Bhadkamkar VA, et al.: Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005, 23:16–21.PubMedCrossRefGoogle Scholar
  42. 42.
    Mikolajczyk SD, Millar LS, Wang TJ, et al.: “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41–45.PubMedCrossRefGoogle Scholar
  43. 43.
    Mikolajczyk SD, Millar LS, Marker KM, et al.: Seminal plasma contains “BPSA,” a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000, 45:271–276.PubMedCrossRefGoogle Scholar
  44. 44.
    Linton HJ, Marks LS, Millar LS, et al.: Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253–259.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.The Baylor Prostate Center, Scott Department of Urology, BaylorCollege of MedicineHoustonUSA

Personalised recommendations